

	<b>DAY 1</b>	<b>DAY 2</b>
840-900	<b>Opening Ceremony</b>	
900-920	Imaging In Glaucoma –R STAMPER	
920-940	New Technologies For Evaluation Of Primary Angle Closure –C LEUNG	Maximizing Medical Treatment and Improving Adherence - R STAMPER
940-10	Glaucoma Optic Nerve Evaluation – J CROWSTON	Neuroprotection In Glaucoma:Where Are We Now? – J CROWSTON
10-1020	Optic Disc & NFL Imaging With OCT:Premises,Promises,Challenges – C LEUNG	Risk Factors Of NTG and Treatment Of NTG – KH PARK
1020-1040	<b>Break</b>	<b>Break</b>
1040-11	<b>POINT-COUNTERPOINT 1:</b>	<b>POINT-COUNTERPOINT 3:</b>
11-1120	<b><i>Optical Coherence Tomography for the Glaucoma Suspect: Routine vs Non-Routine</i></b>	<b><i>First-line Medical Therapy: Monotherapy or Monobottle?</i></b>
1120-1140		
1140-12	Ocular Surface Disease - J CROWSTON	Biometry Of The Asian Eye Over Time - N CONGDON
12-1220	CCT & Corneal Hysteresis: Where Are We Now? – N CONGDON	Glaucoma Co-morbidity:More Than Meets The Eye -J CROWSTON
1220-1240	Progress In Corneal Biomechanics and IOP Measurements – C LEUNG	<b>Lunch</b>
1240-100	<b>Lunch</b>	<b>Lunch</b>
100-120	<b>Lunch</b>	<b>Lunch</b>
120-140	<b>Lunch</b>	New Surgical Approaches In Glaucoma Therapy – R STAMPER
140-200	Updates On Disc Hemorrhage:Prevalence And Significance – KH PARK	Management Of Cataract And Glaucoma – N CONGDON
200-220	How To Detect Glaucoma Progression In Clinical Practice – C LEUNG	Recognizing And Managing The Failing Filter and Updates On Anti-fibrosis Therapies – J CROWSTON
220-240	Best Ways To Assess Progression On Visual Field –R STAMPER	Optimizing Surgical Outcomes In Trabeculectomy – C LEUNG
240-300	Detection Of RNFL Progression – KH PARK	<b>Break</b>
300-320	<b>Break</b>	<b>POINT-COUNTERPOINT 4:</b>  <b><i>IOP elevation after Trabeculectomy: Medications vs Needling</i></b>
320-340	LPI and ALPI – KH PARK	
340-400	Role Of SLT In Glaucoma Management - LEUNG	
400-420	<b>POINT-COUNTERPOINT 2:</b>	Glaucoma Implants
420-440	<b><i>IOP Elevation after Laser Iridotomy: Medications vs Phaco</i></b>	<b>POINT-COUNTERPOINT 5:</b>  <b><i>Marginally controlled glaucoma with visually significant cataract: Phacotrab vs Phaco alone</i></b>
440-500		
	<b>Fellowship Night</b>	<b>Closing Ceremony</b>